vs
Apellis Pharmaceuticals, Inc.（APLS）与凯旋（TFIN）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是凯旋的1.7倍（$199.9M vs $120.1M），凯旋同比增速更快（16.0% vs -5.9%），过去两年凯旋的营收复合增速更高（9.0% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
凯旋汽车公司是19至20世纪活跃于英国的汽车与发动机制造企业，品牌起源可追溯到1885年。来自纽伦堡的齐格弗里德·贝特曼在伦敦成立公司，最初从欧洲进口自行车以自有商标销售，次年商标正式定为“凯旋”，1889年开始自主生产自行车。
APLS vs TFIN — 直观对比
营收规模更大
APLS
是对方的1.7倍
$120.1M
营收增速更快
TFIN
高出21.9%
-5.9%
两年增速更快
TFIN
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $120.1M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | 16.0% |
| 净利润同比 | -62.2% | 400.6% |
| 每股收益（稀释后） | $-0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSTFIN
| Q4 25 | $199.9M | $120.1M | ||
| Q3 25 | $458.6M | $109.3M | ||
| Q2 25 | $178.5M | $108.1M | ||
| Q1 25 | $166.8M | $101.6M | ||
| Q4 24 | $212.5M | $103.6M | ||
| Q3 24 | $196.8M | $106.2M | ||
| Q2 24 | $199.7M | $105.1M | ||
| Q1 24 | $172.3M | $101.0M |
净利润APLSTFIN
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $1.7M | ||
| Q2 25 | $-42.2M | $4.4M | ||
| Q1 25 | $-92.2M | $17.0K | ||
| Q4 24 | $-36.4M | $3.8M | ||
| Q3 24 | $-57.4M | $5.3M | ||
| Q2 24 | $-37.7M | $2.7M | ||
| Q1 24 | $-66.4M | $4.2M |
营业利润率APLSTFIN
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | 1.2% | ||
| Q2 25 | -18.6% | 7.3% | ||
| Q1 25 | -50.0% | 0.1% | ||
| Q4 24 | -12.3% | 5.6% | ||
| Q3 24 | -24.0% | 5.9% | ||
| Q2 24 | -14.7% | 3.4% | ||
| Q1 24 | -36.0% | 4.7% |
净利率APLSTFIN
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 1.6% | ||
| Q2 25 | -23.6% | 4.1% | ||
| Q1 25 | -55.3% | 0.0% | ||
| Q4 24 | -17.1% | 3.7% | ||
| Q3 24 | -29.2% | 5.0% | ||
| Q2 24 | -18.9% | 2.6% | ||
| Q1 24 | -38.5% | 4.1% |
每股收益（稀释后）APLSTFIN
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | $0.04 | ||
| Q2 25 | $-0.33 | $0.15 | ||
| Q1 25 | $-0.74 | $-0.03 | ||
| Q4 24 | $-0.30 | $0.13 | ||
| Q3 24 | $-0.46 | $0.19 | ||
| Q2 24 | $-0.30 | $0.08 | ||
| Q1 24 | $-0.54 | $0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $248.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $941.8M |
| 总资产 | $1.1B | $6.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSTFIN
| Q4 25 | $466.2M | $248.5M | ||
| Q3 25 | $479.2M | $147.2M | ||
| Q2 25 | $370.0M | $282.3M | ||
| Q1 25 | $358.4M | $502.9M | ||
| Q4 24 | $411.3M | $330.1M | ||
| Q3 24 | $396.9M | $489.3M | ||
| Q2 24 | $360.1M | $500.7M | ||
| Q1 24 | $325.9M | $417.0M |
总债务APLSTFIN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSTFIN
| Q4 25 | $370.1M | $941.8M | ||
| Q3 25 | $401.2M | $919.3M | ||
| Q2 25 | $156.3M | $912.4M | ||
| Q1 25 | $164.2M | $893.9M | ||
| Q4 24 | $228.5M | $890.9M | ||
| Q3 24 | $237.1M | $885.8M | ||
| Q2 24 | $264.3M | $874.2M | ||
| Q1 24 | $266.7M | $872.3M |
总资产APLSTFIN
| Q4 25 | $1.1B | $6.4B | ||
| Q3 25 | $1.1B | $6.4B | ||
| Q2 25 | $821.4M | $6.5B | ||
| Q1 25 | $807.3M | $6.3B | ||
| Q4 24 | $885.1M | $5.9B | ||
| Q3 24 | $901.9M | $5.9B | ||
| Q2 24 | $904.5M | $5.8B | ||
| Q1 24 | $831.9M | $5.6B |
负债/权益比APLSTFIN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $67.1M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSTFIN
| Q4 25 | $-14.2M | $67.1M | ||
| Q3 25 | $108.5M | $24.4M | ||
| Q2 25 | $4.4M | $9.8M | ||
| Q1 25 | $-53.4M | $-3.6M | ||
| Q4 24 | $19.4M | $58.5M | ||
| Q3 24 | $34.1M | $26.6M | ||
| Q2 24 | $-8.3M | $21.9M | ||
| Q1 24 | $-133.0M | $-10.7M |
自由现金流APLSTFIN
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | $22.4M | ||
| Q2 25 | $4.4M | $6.8M | ||
| Q1 25 | $-53.4M | $-7.9M | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | $25.8M | ||
| Q2 24 | $-8.4M | $-31.9M | ||
| Q1 24 | $-133.3M | — |
自由现金流率APLSTFIN
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | 20.5% | ||
| Q2 25 | 2.5% | 6.2% | ||
| Q1 25 | -32.0% | -7.7% | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | 24.3% | ||
| Q2 24 | -4.2% | -30.3% | ||
| Q1 24 | -77.3% | — |
资本支出强度APLSTFIN
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | 1.8% | ||
| Q2 25 | 0.0% | 2.8% | ||
| Q1 25 | 0.0% | 4.2% | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | 0.8% | ||
| Q2 24 | 0.0% | 51.1% | ||
| Q1 24 | 0.2% | — |
现金转化率APLSTFIN
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 14.29× | ||
| Q2 25 | — | 2.22× | ||
| Q1 25 | — | -212.82× | ||
| Q4 24 | — | 15.25× | ||
| Q3 24 | — | 4.97× | ||
| Q2 24 | — | 7.95× | ||
| Q1 24 | — | -2.58× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
TFIN
暂无分部数据
